by admin | Mar 17, 2025 | News
Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy Mont-Saint-Guibert, Belgium (March 17, 2025) – EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising...
by admin | Jan 8, 2025 | News
Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletionAt 28 days after a single dose of ESO-T01, no cancer cells were detected in the bone marrowESO-T01 is being developed in...
by admin | Dec 11, 2024 | News
ESO-T01 is the first in vivoBCMA CAR-T candidate to reach the clinical stage Early clinical data are expected in second half of 2025 Mont-Saint-Guibert, Belgium (December 11, 2024) – EsoBiotec SA, a biotechnology company empowering cells in vivo to fight cancer, today...
by admin | Dec 11, 2024 | Person
Sophie Amsellem-Bosq CMC and Manufacturing Lead Advisor Dr. Amsellem-Bosq has more than 20 years of experience in cell and gene therapy across the entire value chain from discovery through clinical development and manufacturing, up to bedside. Sophie served as Global...
by admin | Dec 11, 2024 | Person
Armen Asatryan, MD Clinical Development Lead Advisor Dr. Armen Asatryan is an experienced clinical research and development leader trained as a physician-scientist and more than 25 years of combined experience in clinical medicine and pharmaceutical/biotechnology...
